Bid Target Monash IVF's Stock Trades Near Fair Value -- Market Talk

Dow Jones12-05 06:57

2257 GMT - Macquarie says Monash IVF's share price appears close to fair value, as the in vitro fertilization specialist waits to see if Genesis Capital and Washington H. Soul Pattinson bid again. Monash IVF ended Thursday at A$0.865, above the consortium's A$0.80/share offer that was rejected. Monash IVF said the bid materially undervalues the company. However, Macquarie points out that while the consortium's offer is lower relative to past deals in the sector, the outlook for IVF has changed since 2022. "Incidents have potentially weighed on customer acquisition and triggered greater regulatory scrutiny, likely increasing compliance costs as additional safeguards are implemented," Macquarie says. Aggressive competition from unlisted peers, especially in Victoria state, adds pressure. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

December 04, 2025 17:57 ET (22:57 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589853530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 06:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589853530","market":"sh","top_or_hot":-1,"title":"Bid Target Monash IVF's Stock Trades Near Fair Value -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2257 GMT - <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> says <a href=\"https://laohu8.com/S/MNIVF\">Monash IVF</a>'s share price appears close to fair value, as the in vitro fertilization specialist waits to see if Genesis Capital and <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a> bid again. Monash IVF ended Thursday at A$0.865, above the consortium's A$0.80/share offer that was rejected. Monash IVF said the bid materially undervalues the company. However, Macquarie points out that while the consortium's offer is lower relative to past deals in the sector, the outlook for IVF has changed since 2022. \"Incidents have potentially weighed on customer acquisition and triggered greater regulatory scrutiny, likely increasing compliance costs as additional safeguards are implemented,\" Macquarie says. Aggressive competition from unlisted peers, especially in <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a> state, adds pressure. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 04, 2025 17:57 ET (22:57 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bid Target Monash IVF's Stock Trades Near Fair Value -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBid Target Monash IVF's Stock Trades Near Fair Value -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-05 06:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2257 GMT - <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> says <a href=\"https://laohu8.com/S/MNIVF\">Monash IVF</a>'s share price appears close to fair value, as the in vitro fertilization specialist waits to see if Genesis Capital and <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a> bid again. Monash IVF ended Thursday at A$0.865, above the consortium's A$0.80/share offer that was rejected. Monash IVF said the bid materially undervalues the company. However, Macquarie points out that while the consortium's offer is lower relative to past deals in the sector, the outlook for IVF has changed since 2022. \"Incidents have potentially weighed on customer acquisition and triggered greater regulatory scrutiny, likely increasing compliance costs as additional safeguards are implemented,\" Macquarie says. Aggressive competition from unlisted peers, especially in <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a> state, adds pressure. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 04, 2025 17:57 ET (22:57 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVF","symbol_name":"INVO Fertility, Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2589853530","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589853530","pubTimestamp":1764889020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2257 GMT - Macquarie says Monash IVF's share price appears close to fair value, as the in vitro fertilization specialist waits to see if Genesis Capital and Washington H. Soul Pattinson bid again. Monash IVF ended Thursday at A$0.865, above the consortium's A$0.80/share offer that was rejected. Monash IVF said the bid materially undervalues the company. However, Macquarie points out that while the consortium's offer is lower relative to past deals in the sector, the outlook for IVF has changed since 2022. \"Incidents have potentially weighed on customer acquisition and triggered greater regulatory scrutiny, likely increasing compliance costs as additional safeguards are implemented,\" Macquarie says. Aggressive competition from unlisted peers, especially in Victoria state, adds pressure. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVF":"INVO Fertility, Inc","BK7113":"保健护理机构","BK7105":"多领域控股","BK4082":"医疗保健设备","MVF.AU":"MONASH IVF GROUP LTD","SOL.AU":"WASHINGTON H. SOUL PATTINSON","BK7508":"医药生物股","BK7083":"煤与消费用燃料"},"translate_title":"出价目标Monash IVF的股票交易价格接近公允价值——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MVF.AU":0.9,"IVF":1.5,"SOL.AU":0.9},"content_text":"2257 GMT - Macquarie says Monash IVF's share price appears close to fair value, as the in vitro fertilization specialist waits to see if Genesis Capital and Washington H. Soul Pattinson bid again. Monash IVF ended Thursday at A$0.865, above the consortium's A$0.80/share offer that was rejected. Monash IVF said the bid materially undervalues the company. However, Macquarie points out that while the consortium's offer is lower relative to past deals in the sector, the outlook for IVF has changed since 2022. \"Incidents have potentially weighed on customer acquisition and triggered greater regulatory scrutiny, likely increasing compliance costs as additional safeguards are implemented,\" Macquarie says. Aggressive competition from unlisted peers, especially in Victoria state, adds pressure. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 17:57 ET (22:57 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589853530","isCrawlerRequest":true}